Chemotherapy for liver cancer in Republic of Korea: Our Best Clinics and Costs 2026

South Korea treats liver cancer using Transarterial Chemoembolization (TACE) as the primary localized chemotherapy, alongside advanced systemic targeted therapies like Lenvatinib and Atezolizumab plus Bevacizumab. Clinics in Seoul follow 2022 KLCA-NCC guidelines, prioritizing organ preservation through hepatic arterial infusion and multidisciplinary care.

• Localized chemotherapy: TACE uses Doxorubicin or Cisplatin delivered directly to tumors to protect liver function.
• Infusion techniques: Hepatic Arterial Infusion Chemo (HAIC) treats advanced cases involving portal vein invasion.
• First-line systemic: Atezolizumab combined with Bevacizumab is now the preferred first-line systemic therapy.
• Oral targeted agents: Lenvatinib and Sorafenib serve as standard oral options for unresectable liver cancer.

Bookimed Expert Insight: While many Western centers move quickly to systemic drugs, Seoul's top hospitals like Asan Medical Center favor localized TACE. This approach reflects their high volume of organ transplants and specialized focus on liver preservation. For patients, this often means fewer systemic side effects compared to traditional intravenous chemotherapy cycles.

Patient Consensus: Many patients find TACE is the preferred starting point because it is less toxic than systemic chemo. They recommend preparing for skin-related side effects when transitioning to oral targeted therapies like Lenvatinib.

Patients must undergo Hepatitis B testing before starting chemotherapy to prevent viral reactivation. Immunosuppressive drugs can trigger dormant Hepatitis B into active liver inflammation or failure. This screening is a mandatory safety protocol in South Korea, especially given higher regional prevalence rates compared to Western countries.

• Core testing panel: Screens for HBsAg, anti-HBs, and anti-HBc markers to identify past or current infections.
• Reactivation risks: Immunosuppression can cause a 10% to 20% reactivation risk in Hepatitis B carriers.
• Preventative medication: Doctors prescribe antiviral prophylaxis like entecavir or tenofovir if the patient tests positive.
• Treatment timeline: Antiviral therapy typically starts 1 to 4 weeks before the first chemotherapy session.

Bookimed Expert Insight: South Korean hospitals like Asan Medical Center and Seoul National University Hospital enforce stricter screening than many US clinics. Data shows these top-tier centers treat several thousand oncology patients daily. Their high-volume experience leads to zero tolerance for skips in Hepatitis B serology. This rigorous approach effectively eliminates the risk of fulminant hepatitis during cancer treatment.

Patient Consensus: Patients emphasize that Hepatitis B testing is non-negotiable and strictly monitored. Some reported three-month delays for antiviral stabilizer treatment after unexpected positive results, which ultimately ensured their safety during chemotherapy.

South Korea reports a 40.4% five-year relative survival rate for liver cancer, with hepatocellular carcinoma (HCC) reaching 44.7%. These high outcomes stem from the National Cancer Screening Program and advanced surgical interventions at JCI-accredited centers like Severance Hospital and Asan Medical Center.

• Localized stage: Five-year survival rates reach 87.3% to 89.3% when treated with surgical resection.
• Regional spread: Survival remains high at 63.0% to 68.6% for patients undergoing surgical intervention.
• Advanced cases: Metastatic cancer survival is approximately 20.0%, often managed with drug-based immunotherapy.
• Screening impact: Early detection through national programs for chronic hepatitis patients significantly improves prognosis.

Bookimed Expert Insight: South Korea's survival lead is driven by massive procedure volumes at `Big Five` hospitals. Asan Medical Center alone treats over 11,800 outpatients daily. This concentrated expertise allows surgeons to maintain higher success rates for complex liver resections and transplants.

Patient Consensus: Patients emphasize that early-stage diagnosis through screening is the most critical factor for survival. Many highlight that newer immunotherapy combinations are now preferred over traditional chemotherapy for advanced cases.

Seoul's Big 5 hospitals, including Asan Medical Center and Samsung Medical Center, are the most recommended for liver cancer care. These institutions lead globally in surgical volumes, living donor transplants, and advanced therapies like proton beam irradiation, achieving five-year survival rates exceeding 75%.

• Asan Medical Center: Performs 17% of Korea's liver cancer surgeries with 0.19% post-operative mortality.
• Samsung Medical Center: Ranked 3rd globally for oncology, pioneering precise proton therapy for tumors.
• Seoul National University: Asia's leader in transarterial radioembolization with 85.8% transplant survival rates.
• Severance Hospital: First dedicated Korean cancer center specializing in heavy ion and robotic surgery.
• Digital integration: Bundang Hospital uses BESTcare systems to eliminate medical errors during complex treatments.

Bookimed Expert Insight: While prestige stays with the Big 5, SNU Bundang Hospital offers a digital edge. Their 1st-in-Korea digital system actively prevents medication errors. This is critical for liver patients managing complex, multi-drug chemotherapy regimens alongside viral hepatitis treatments.

Patient Consensus: Patients emphasize that combining TACE with systemic chemotherapy yields the best outcomes. They strongly recommend booking 3–6 months ahead and ensuring all viral hepatitis screenings are completed before arrival.

Intravenous chemotherapy sessions in South Korea typically last between 2 to 8 hours. For liver cancer protocols like FOLFOX, outpatient sessions generally span 4 hours including premedication. Duration depends on the specific drug regimen, dose escalation, and necessary post-infusion monitoring at JCI-accredited Seoul hospitals.

• Session range: Standard infusions typically last 2 to 5 hours for most patients.
• Pre-treatment prep: Blood work and anti-nausea medication add 1 to 2 hours initially.
• Liver protocols: FOLFOX regimens often require 4-hour sessions every 2 weeks in outpatient units.
• Rapid administration: Specific bolus injections may be completed in 15 to 30 minutes.

Bookimed Expert Insight: High patient volumes at centers like Asan Medical Center, which treats over 11,800 outpatients daily, have streamlined infusion logistics. Data shows Korean nursing efficiency and digital systems like BESTcare at SNUBH significantly reduce wait times compared to US facilities. While a session might be 4 hours, the total facility time is often shorter due to rapid laboratory processing.

Patient Consensus: Patients note that hydration bags can unexpectedly double the session time. Most recommend bringing entertainment and snacks, as the efficient outpatient setup keeps the process moving quickly without long delays.

South Korea prioritises immunotherapy-based combinations as the first-line systemic treatment for advanced liver cancer. Common protocols include Atezolizumab plus Bevacizumab and Durvalumab plus Tremelimumab. These therapies significantly improve survival rates for unresectable or metastatic hepatocellular carcinoma. They offer better results than traditional chemotherapy or molecularly targeted agents alone.

• Immunotherapy standards: Atezolizumab and Bevacizumab are the primary first-line combination in Seoul hospitals.
• Combination regimens: The STRIDE regimen uses Durvalumab and Tremelimumab for primary systemic therapy.
• Targeted alternatives: Lenvatinib remains a major option for patients unsuitable for immunotherapy-based protocols.
• Clinical partnerships: Severance Hospital oncology teams collaborate with MD Anderson for advanced treatment protocols.

Bookimed Expert Insight: South Korea leads in liver cancer innovation. This is due to massive patient volumes and digital integration. Seoul National University Hospital alone completes 1,000+ liver transplants. Major centres like Asan Medical Center maintain a 98% liver transplant success rate. This experience translates to highly precise systemic treatment plans. They often outpace global averages.

Patient Consensus: Patients in South Korea found that oncologists follow global legal standards. They also found that these doctors prioritise immunotherapy over older chemotherapy. Sharing pathology slides and seeking second opinions were easy at major international clinics.

South Korea uses traditional chemotherapy for liver cancer, typically alongside targeted therapies or locoregional treatments. Oncology centres in Seoul now prefer immunotherapy combinations, like Atezolizumab plus Bevacizumab, for advanced cases. Conventional systemic chemotherapy is often replaced by precise, direct-to-tumour delivery methods. This approach is common in specialised JCI-accredited facilities.

• Regional chemotherapy: Specialists use TACE to deliver drugs directly to liver tumours during procedures.
• Targeted therapy: Doctors prescribe Lenvatinib or Nexavar to attack specific cancer cell proteins.
• Dual protocols: Clinics combine systemic drugs with immunotherapy to improve survival in metastatic cases.
• Complementary care: Hospitals may integrate traditional Korean medicine to manage nausea and fatigue.

Bookimed Expert Insight: South Korea’s liver cancer outcomes are driven by massive volume at centres like Severance Hospital. This hospital handles 40,000 operations annually. Many top-tier Seoul clinics partner with US institutions like MD Anderson. This collaboration means patients receive the newest global immunotherapy protocols, rather than outdated standalone chemotherapy regimens.

Patient Consensus: Patients can expect doctors in Seoul to recommend modern immunotherapy or targeted drugs. These are preferred over traditional chemotherapy for effectiveness. They will likely discuss non-surgical options for liver-confined tumours, such as Y90 or ablation.

Liver cancer patients in South Korea experience some of the world's best clinical outcomes. The five-year relative survival rate has tripled to 32.8% recently. Highly specialised centres like Asan Medical Center report a 98% success rate for liver transplants. They also lead in advanced immunotherapy for hepatocellular carcinoma.

• Survival rates: The five-year relative survival rate increased from 10.7% to over 32.8% recently.
• Transplant success: Asan Medical Center maintains a 98% success rate for complex liver transplant procedures.
• Advanced techniques: Specialists prefer immunotherapy-based systemic therapy over traditional chemotherapy for advanced hepatocellular carcinoma.
• High volume: Seoul National University Hospital has completed over 1,000 successful liver transplants to date.

Bookimed Expert Insight: While clinical outcomes lead globally, Korean hospitals typically require full diagnostic re-testing on arrival. Patients should expect new imaging and blood work to take two to four weeks. This protocol provides precise staging before starting intensive treatment like immunotherapy or robotic resection.

Patient Consensus: South Korea offers premier liver cancer care at university-affiliated centres in Seoul. Having a local contact helps with hospital navigation and admission during the stay.

TACE in South Korea treats intermediate-stage liver cancer when surgical resection is not possible. It is a minimally invasive treatment. At JCI-accredited Seoul hospitals, specialists deliver chemotherapy directly to tumours via the hepatic artery. Embolic agents block the blood supply to starve cancer cells.

• Techniques available: Providers offer conventional TACE with Lipiodol. They may also use drug-eluting bead TACE (DEB-TACE) for targeted delivery.
• Clinical expertise: Hospitals like Seoul National University Hospital have performed 1,000+ liver transplants. They also manage high-volume oncology interventions.
• Treatment guidelines: The Korean Liver Cancer Association (KLCA) establishes strict protocols. These cover patient selection and post-treatment care.
• Hospital infrastructure: Leading centres like Asan Medical Center perform 55,000+ yearly surgeries. Their liver transplant success rate is 98%.

Bookimed Expert Insight: While TACE starts from $2,800, South Korea’s oncology power lies in multidisciplinary collaboration. Severance Hospital partners with MD Anderson to manage recurrent tumours. This is why centres like Seoul National University Hospital attract many international patients. They serve 30,000+ annually from 80 countries.

Patient Consensus: Expect post-embolisation syndrome, including pain and fatigue. It peaks around 72 hours after the procedure in Seoul. Most return to light work within days. However, the incision sites take roughly one month to heal completely.